Journals Library

An error occurred retrieving content to display, please try again.

Page not found (404)

Sorry - the page you requested could not be found.

Please choose a page from the navigation or try a website search above to find the information you need.

During the 12 weeks from new diagnosis, the addition of prophylactic levofloxacin to active myeloma treatment significantly reduced febrile episodes and deaths without increasing healthcare associated infections or carriage.

{{author}}{{author}}{{($index < metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Mark T Drayson, Stella Bowcock, Tim Planche, Gulnaz Iqbal, Guy Pratt, Kwee Yong, Jill Wood, Kerry Raynes, Helen Higgins, Bryony Dawkins, David Meads, Claire T Hulme, Anna C Whittaker, Peter Hawkey, Eric Low & Janet A Dunn.

Mark T Drayson 1,*, Stella Bowcock 2, Tim Planche 3, Gulnaz Iqbal 4, Guy Pratt 5, Kwee Yong 6, Jill Wood 4, Kerry Raynes 4, Helen Higgins 4, Bryony Dawkins 7, David Meads 7, Claire T Hulme 7, Anna C Whittaker 8, Peter Hawkey 9, Eric Low 10, Janet A Dunn 4

1 Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK
2 King’s College Hospital NHS Foundation Trust, London, UK
3 Institute of Infection and Immunity, St George’s Hospital, University of London, London, UK
4 Warwick Clinical Trials Unit, University of Warwick, Coventry, UK
5 University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
6 Department of Haematology, University College London Cancer Institute, London, UK
7 Academic Unit of Health Economics, University of Leeds, Leeds, UK
8 School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Birmingham, UK
9 Institute of Microbiology and Infection, University of Birmingham, Birmingham, UK
10 Patient Advocacy, Myeloma UK, Edinburgh, UK
* Corresponding author Email:

Funding: {{metadata.Funding}}

{{metadata.Journal}} Volume: {{metadata.Volume}}, Issue: {{metadata.Issue}}, Published in {{metadata.PublicationDate | date:'MMMM yyyy'}}{{metadata.DOI}}

Citation: {{author}}{{ (($index < metadata.AuthorsArray.length-1) && ($index <=6)) ? ', ' : '' }}{{(metadata.AuthorsArray.length <= 6) ? '.' : '' }} {{(metadata.AuthorsArray.length > 6) ? 'et al.' : ''}} . {{metadata.JournalShortName}} {{metadata.PublicationDate | date:'yyyy'}};{{metadata.Volume}}({{metadata.Issue}})

Crossmark status check

Report Content

The full text of this issue is available as a PDF document from the Toolkit section on this page.

The full text of this issue is available as a PDF document from the Toolkit section on this page.

If you would like to receive a notification when this project publishes in the NIHR Journals Library, please submit your email address below.


Responses to this report

No responses have been published.


If you would like to submit a response to this publication, please do so using the form below:

Comments submitted to the NIHR Journals Library are electronic letters to the editor. They enable our readers to debate issues raised in research reports published in the Journals Library. We aim to post within 14 working days all responses that contribute substantially to the topic investigated, as determined by the Editors.  Non-relevant comments will be deleted.

Your name and affiliations will be published with your comment.

Once published, you will not have the right to remove or edit your response. The Editors may add, remove, or edit comments at their absolute discretion.

By submitting your response, you are stating that you agree to the terms & conditions